Zhongsheng Pharmaceutical announced that it recently received the “Drug Registration Certificate” for ambroxol hydrochloride oral solution approved and issued by the State Drug Administration. Ambroxol hydrochloride oral solution is a medical insurance class B drug. The total sales volume in public hospitals and urban physical pharmacies in China from 2022 to 2024 was 711 million yuan, 818 million yuan, and 850 million yuan respectively. This approval marks that the product has passed the consistency evaluation as a chemical generic drug, further enriching the company's product line in the field of respiratory treatment.

Zhongsheng Pharmaceutical announced that it recently received the “Drug Registration Certificate” for ambroxol hydrochloride oral solution approved and issued by the State Drug Administration. Ambroxol hydrochloride oral solution is a medical insurance class B drug. The total sales volume in public hospitals and urban physical pharmacies in China from 2022 to 2024 was 711 million yuan, 818 million yuan, and 850 million yuan respectively. This approval marks that the product has passed the consistency evaluation as a chemical generic drug, further enriching the company's product line in the field of respiratory treatment.